Immatics Biotechnologies GmbH - Pharmaceuticals & Healthcare - Deals and Alliances Profile

Summary

Immatics Biotechnologies GmbH (Immatics) is a clinical stage biopharmaceutical company that develops drugs for the treatment of cancer. It develops peptide based active immunotherapy drug candidates based on it novel technology, XPRESIDENT discovery platform. The company has active programs in several tumor types including gastric cancer, non-small-cell lung cancer and prostate cancer. Its major drug candidates include IMA101, IMA201, IMA202, IMA203, and IMA300/301 which are focused on the development of three ACT approaches ACTolog, ACTengine, and ACTallo to treat cancer. The company has collaborations with Roche, UTHealth and MorphoSys for the advancement of its drug candidates. Immatics is headquartered in Tuebingen, Germany.

Immatics Biotechnologies GmbH - Pharmaceuticals & Healthcare - Deals and Alliances Profile provides you comprehensive data and trend analysis of the companys Mergers and Acquisitions (M&As), partnerships and financings. The report provides detailed information on Mergers and Acquisitions, Equity/Debt Offerings, Private Equity, Venture Financing and Partnership transactions recorded by the company over a five year period. The report offers detailed comparative data on the number of deals and their value categorized into deal types, sub-sector and regions.

GlobalData derived the data presented in this report from proprietary in-house Pharma eTrack deals database, and primary and secondary research.

Scope

- Financial Deals - Analysis of the companys financial deals including Mergers and Acquisitions, Equity/Debt Offerings, Private Equity, Venture Financing and Partnerships.
- Deals by Year - Chart and table displaying information encompassing the number of deals and value reported by the company by year, for a five year period.
- Deals by Type - Chart and table depicting information including the number of deals and value reported by the company by type such as Mergers and Acquisitions, Equity/Debt Offering etc.
- Deals by Region - Chart and table presenting information on the number of deals and value reported by the company by region, which includes North America, Europe, Asia Pacific, the Middle East and Africa and South and Central America.
- Deals by Sub-sector - Chart and table showing information on the number of deals and value reported by the company, by sub-sector.
- Major Deals - Information on the companys major financial deals. Each such deal has a brief Summary, deal type, deal rationale; and deal financials and target Companys (major public companies) key financial metrics and ratios.
- Business Description - A brief description of the companys operations.
- Key Employees - A list of the key executives of the company.
- Important Locations and Subsidiaries - A list and contact details of key centers of operation and subsidiaries of the company.
- Key Competitors - A list of the key competitors of the company.
- Key Recent Developments - A brief on recent news about the company.

Reasons to Buy

Get detailed information on the companys financial deals that enable you to understand the companys expansion/divestiture and fund requirements
- The profile enables you to analyze the companys financial deals by region, by year, by business segments and by type, for a five year period.

Understand the companys business segments expansion / divestiture strategy
- The profile presents deals from the companys core business segments perspective to help you understand its corporate strategy.

Access elaborate information on the companys recent financial deals that enable you to understand the key deals which have shaped the company
- Detailed information on major recent deals includes a Summary of each deal, deal type, deal rationale, deal financials and Target Companys key financial metrics and ratios.

Equip yourself with detailed information about the companys operations to identify potential customers and suppliers.
- The profile analyzes the companys business structure, locations and subsidiaries, key executives and key competitors.

Stay up-to-date on the major developments affecting the company
- Recent developments concerning the company presented in the profile help you track important events.

Gain key insights into the company for academic or business research
- Key elements such as break up of deals into categories and information on detailed major deals are incorporated into the profile to assist your academic or business research needs.

Note*: Some sections may be missing if data is unavailable for the company.




Immatics Biotechnologies GmbH, Pharmaceuticals & Healthcare, Deals By Year, 2012 to YTD 2018 5
Immatics Biotechnologies GmbH, Pharmaceuticals & Healthcare Deals By Type, 2012 to YTD 2018 6
Immatics Biotechnologies GmbH, Pharmaceuticals & Healthcare, Deals By Region, 2012 to YTD 2018 7
Immatics Biotechnologies GmbH, Pharmaceuticals & Healthcare, Deals By Therapy Area, 2012 to YTD 2018 8
Immatics Biotechnologies GmbH, Pharmaceuticals & Healthcare, Deals Summary, 2012 to YTD 2018 9
Immatics Biotechnologies GmbH, Pharmaceuticals & Healthcare, Deal Details 10
Venture Financing 10
Immatics Biotech Raises USD58 Million in Series E Financing 10
immatics biotech Raises Additional USD29.8 Million in Second Tranche of Series D Financing 11
Partnerships 12
MorphoSys Enters into Agreement with Immatics Biotech 12
Licensing Agreements 13
Roche Exercises Option for Licensing Agreement with Immatics 13
Amgen Enters into Licensing Agreement with Immatics Biotech 14
Immatics Biotech Enters into Licensing Agreement with Sanquin Blood Supply Foundation 15
Immatics Biotech, Cancer Research UK and Cancer Research Technology Enter into Licensing Agreement 16
Equity Offering 17
Immatics US Raises USD10 Million in Financing 17
Immatics Biotechnologies GmbH - Key Competitors 18
Immatics Biotechnologies GmbH - Key Employees 19
Immatics Biotechnologies GmbH - Locations And Subsidiaries 20
Head Office 20
Other Locations & Subsidiaries 20
Joint Venture 20
Recent Developments 21
Corporate Communications 21
Jan 17, 2018: Immatics Appoints Thomas Ulmer as CFO 21
Appendix 22
Methodology 22
About GlobalData 22
Contact Us 22
Disclaimer 22

List Of Tables

List of Tables
Immatics Biotechnologies GmbH, Pharmaceuticals & Healthcare, Key Facts 2
Immatics Biotechnologies GmbH, Pharmaceuticals & Healthcare, Deals By Year, 2012 to YTD 2018 5
Immatics Biotechnologies GmbH, Pharmaceuticals & Healthcare Deals By Type, 2012 to YTD 2018 6
Immatics Biotechnologies GmbH, Pharmaceuticals & Healthcare, Deals By Region, 2012 to YTD 2018 7
Immatics Biotechnologies GmbH, Deals By Therapy Area, 2012 to YTD 2018 8
Immatics Biotechnologies GmbH, Pharmaceuticals & Healthcare, Deals Summary, 2012 to YTD 2018 9
Immatics Biotech Raises USD58 Million in Series E Financing 10
immatics biotech Raises Additional USD29.8 Million in Second Tranche of Series D Financing 11
MorphoSys Enters into Agreement with Immatics Biotech 12
Roche Exercises Option for Licensing Agreement with Immatics 13
Amgen Enters into Licensing Agreement with Immatics Biotech 14
Immatics Biotech Enters into Licensing Agreement with Sanquin Blood Supply Foundation 15
Immatics Biotech, Cancer Research UK and Cancer Research Technology Enter into Licensing Agreement 16
Immatics US Raises USD10 Million in Financing 17
Immatics Biotechnologies GmbH, Key Competitors 18
Immatics Biotechnologies GmbH, Key Employees 19
Immatics Biotechnologies GmbH, Other Locations 20
Immatics Biotechnologies GmbH, Joint Venture 20

List Of Figures

List of Figures
Immatics Biotechnologies GmbH, Pharmaceuticals & Healthcare, Deals by Type, 2012 to YTD 2018 2
Immatics Biotechnologies GmbH, Pharmaceuticals & Healthcare, Deals By Year, 2012 to YTD 2018 2
Immatics Biotechnologies GmbH, Pharmaceuticals & Healthcare, Deals By Region, 2012 to YTD 2018 2
Immatics Biotechnologies GmbH, Pharmaceuticals & Healthcare, Deals By Therapy Area, 2012 to YTD 2018 2
Immatics Biotechnologies GmbH, Pharmaceuticals & Healthcare, Deals By Year, 2012 to YTD 2018 5
Immatics Biotechnologies GmbH, Pharmaceuticals & Healthcare, Deals by Type, 2012 to YTD 2018 6
Immatics Biotechnologies GmbH, Pharmaceuticals & Healthcare, Deals By Region, 2012 to YTD 2018 7
Immatics Biotechnologies GmbH, Pharmaceuticals & Healthcare, Deals By Therapy Area, 2012 to YTD 2018 8

Immatics Biotechnologies GmbH - Mergers and Acquisitions (MandA), Partnerships and Alliances and Investment Report

Immatics Biotechnologies GmbH - Mergers & Acquisitions (M&A), Partnerships & Alliances and Investment ReportThe Immatics Biotechnologies GmbH Mergers & Acquisitions (M&A), Partnerships & Alliances and Investments report includes business description,

USD 350 View Report

Immatics Biotechnologies GmbH - Pharmaceuticals and Healthcare - Deals and Alliances Profile

Immatics Biotechnologies GmbH (Immatics) is a clinical stage biopharmaceutical company that develops drugs for the treatment of cancer. It develops peptide based active immunotherapy drug candidates based on it novel

USD 250 View Report

Immatics Biotechnologies GmbH - Mergers and Acquisitions (MandA), Partnerships and Alliances and Investment Report

Immatics Biotechnologies GmbH - Mergers & Acquisitions (M&A), Partnerships & Alliances and Investment ReportThe Immatics Biotechnologies GmbH Mergers & Acquisitions (M&A), Partnerships & Alliances and Investments report includes business description,

USD 350 View Report

Immatics Biotechnologies GmbH - Pharmaceuticals and Healthcare - Deals and Alliances Profile

Immatics Biotechnologies GmbH (Immatics) is a clinical stage biopharmaceutical company that develops drugs for the treatment of cancer. It develops peptide based active immunotherapy drug candidates based on it novel

USD 250 View Report

Your are not allow to send sample request

Fill The Form For Sample Request

Note : * Kindly provide us with your company id and get the sample reports at the earliest.

There is no Reviews available